Thelansis

Acute Gout Market Outlook Thelansis’s “Acute Gout Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Gout treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed ex...

  Acute Gout Market Outlook Thelansis’s “Acute Gout Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Gout treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acute Gout Overview Acute gout attacks manifest swiftly, reaching peak joint pain within 24 hours. Remission usually begins within 5 to 12 days without intervention, but complete resolution may take longer. Most attacks are monoarticular, with the first metatarsophalangeal joint being the initial site in approximately 50% of cases. While the pain typically peaks within 24 hours, chronic or variable intensity pain is more prevalent in patients with long-standing disease. G...

  Acute gout attacks manifest swiftly, reaching peak joint pain within 24 hours. Remission usually begins within 5 to 12 days without intervention, but complete resolution may take longer. Most attacks are monoarticular, with the first metatarsophalangeal joint being the initial site in approximately 50% of cases. While the pain typically peaks within 24 hours, chronic or variable intensity pain is more prevalent in patients with long-standing disease. Gout treatment involves addressing the pain and inflammation of acute attacks and long-term management focused on lowering serum urate levels. Gout patients, often older with multiple comorbidities, face challenges due to accompanying health conditions like diabetes and cardiovascular disease. Diagnosing gout relies on clinical signs, including sudden pain onset, past arthritis attacks, first MTP involvement, and elevated serum urate. However, not all criteria must be present. The ACR recommends pharmacologic therapy as the primary...